Literature DB >> 25711523

Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.

Francesca Bianchi1,2, Marianna Sasso1, Federica Turdo1, Giovanni L Beretta3, Patrizia Casalini1, Cristina Ghirelli1, Lucia Sfondrini2, Sylvie Ménard1, Elda Tagliabue1, Manuela Campiglio1.   

Abstract

The tumor-suppressor protein fragile histidine triad (Fhit) exerts its functions in the cytoplasm, although some reports suggest that it may also act in the nucleus. We previously showed that cytosolic Fhit protein levels in cancer cell lines stimulated to proliferate were reduced by proteasomal degradation. Here, we demonstrate that Fhit is physiologically present in the nucleus of breast cancer cell lines and tissues at a low level and that proliferative stimulation increases nuclear levels. Breast cancer cells expressing the FhitY114F mutant, which do not undergo proteasomal degradation, contained mutated Fhit in the nucleus, while cells treated with a proteasome inhibitor accumulated nuclear Fhit during proliferation. Thus, Fhit nuclear shuttling and proteasome degradation phenomena occur independently. When Fhit was coupled to a nuclear localization sequence, the proliferation rate of the transfected cells increased together with levels of proliferation pathway mediators cyclin D1, phospho-MAPK, and phospho-STAT3. Fhit nuclear translocation upon mitogenic stimulation may represent a new regulatory mechanism that allows rapid restoration of Fhit cytoplasmic levels and promotes the proliferation cascade activated by mitogenic stimulation.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25711523     DOI: 10.1002/jcp.24968

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.

Authors:  Eugenio Gaudio; Francesco Paduano; Apollinaire Ngankeu; Francesco Ortuso; Francesca Lovat; Sandra Pinton; Sabrina D'Agostino; Nicola Zanesi; Rami I Aqeilan; Pietro Campiglia; Ettore Novellino; Stefano Alcaro; Carlo M Croce; Francesco Trapasso
Journal:  Oncotarget       Date:  2016-05-24

2.  The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.

Authors:  Luca Forte; Federica Turdo; Cristina Ghirelli; Piera Aiello; Patrizia Casalini; Marilena Valeria Iorio; Elvira D'Ippolito; Patrizia Gasparini; Roberto Agresti; Beatrice Belmonte; Gabriella Sozzi; Lucia Sfondrini; Elda Tagliabue; Manuela Campiglio; Francesca Bianchi
Journal:  BMC Cancer       Date:  2018-05-23       Impact factor: 4.430

3.  HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.

Authors:  Tiziana Triulzi; Luca Forte; Viola Regondi; Martina Di Modica; Cristina Ghirelli; Maria Luisa Carcangiu; Lucia Sfondrini; Andrea Balsari; Elda Tagliabue
Journal:  Oncoimmunology       Date:  2018-09-21       Impact factor: 8.110

4.  Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors.

Authors:  Roberto Agresti; Tiziana Triulzi; Marianna Sasso; Cristina Ghirelli; Piera Aiello; Ilona Rybinska; Manuela Campiglio; Lucia Sfondrini; Elda Tagliabue; Francesca Bianchi
Journal:  Cells       Date:  2019-02-19       Impact factor: 6.600

5.  Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity.

Authors:  Francesca Bianchi; Michele Sommariva; Valentino Le Noci; Simone Camelliti; Nicoletta Gagliano; Marta Giussani; Andrea Balsari; Elda Tagliabue; Lucia Sfondrini
Journal:  PLoS One       Date:  2021-03-29       Impact factor: 3.240

6.  Chemical Proteomics of the Tumor Suppressor Fhit Covalently Bound to the Cofactor Ap3A Elucidates Its Inhibitory Action on Translation.

Authors:  Doreen Herzog; Jasmin Jansen; Maite Mißun; Kay Diederichs; Florian Stengel; Andreas Marx
Journal:  J Am Chem Soc       Date:  2022-05-06       Impact factor: 16.383

7.  CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.

Authors:  Federica Turdo; Francesca Bianchi; Patrizia Gasparini; Marco Sandri; Marianna Sasso; Loris De Cecco; Luca Forte; Patrizia Casalini; Piera Aiello; Lucia Sfondrini; Roberto Agresti; Maria Luisa Carcangiu; Ilaria Plantamura; Gabriella Sozzi; Elda Tagliabue; Manuela Campiglio
Journal:  Oncotarget       Date:  2016-10-25

8.  Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients.

Authors:  Francesca Bianchi; Massimo Milione; Patrizia Casalini; Giovanni Centonze; Valentino M Le Noci; Chiara Storti; Spyridon Alexiadis; Mauro Truini; Gabriella Sozzi; Ugo Pastorino; Andrea Balsari; Elda Tagliabue; Lucia Sfondrini
Journal:  Sci Rep       Date:  2019-10-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.